Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
RB001
The First People's Hospital of Lianyungang
Phelan-McDermid Syndrome
1 trial -
Regional lymph node radiotherapy (RNI) including the axilla
The First People's Hospital of Lianyungang
Axillary Lymph Node Dissection
1 trial -
Regorafenib and Sintilimab in combination with electroacupuncture
The First People's Hospital of Lianyungang
Colorectal Cancer Metastatic
1 trial -
Remimazolam
The First People's Hospital of Lianyungang
Sedation and Analgesia
1 trial -
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Respiratory monitoring
The First People's Hospital of Lianyungang
Post-Op Complication
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Romiplostim N01
The First People's Hospital of Lianyungang
Primacy Immune Thrombocytopenia
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Surgery
1 trial -
Routine Medication
The First People's Hospital of Lianyungang
Generalized Anxiety Disorder
1 trial -
Ruxolitinib+Calcineurin inhibitor+Methotrexate
The First People's Hospital of Lianyungang
Graft Versus Host Disease
1 trial -
S-ketamine
The First People's Hospital of Lianyungang
Opioid Use, Unspecified
1 trial -
SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
The First People's Hospital of Lianyungang
SARS-CoV-2
1 trial -
SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
The First People's Hospital of Lianyungang
SARS-CoV-2
1 trial -
SHAPE
The First People's Hospital of Lianyungang
Liver Cirrhosis
1 trial -
SLE group
The First People's Hospital of Lianyungang
Lupus Nephritis
1 trial -
SPECT/CT imaging with 99mTc-P137 nuclide probe
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
SSRI
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
SSRIs
The First People's Hospital of Lianyungang
Major Depressive Disorder
2 trials -
Secukinumab 300 MG; Tofacitinib 11mg
The First People's Hospital of Lianyungang
Hidradenitis Suppurativa
1 trial -
Selective Serotonin Reuptake Inhibitors (SSRIs)
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Senl_B19 autologous CAR-T (S1904) treatment
The First People's Hospital of Lianyungang
Relapsed Adult ALL
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources